Proactive Investors - Run By Investors For Investors

Cosmos Holdings welcomes prominent oncologist to advisory board

Dr. Ioannis Dedes is a founding member of the Society of Interventional Oncology
pills
Cosmos is an international pharmaceutical company with offices and distribution centers in Greece and the United Kingdom

Cosmos Holdings Inc (OTCQB:COSM) is bolstering its advisory board with the appointment of Dr. Ioannis Dedes, a prominent radiologist and oncologist.

Dr. Dedes is a founding member of the Society of Interventional Oncology and a director of the Endovascular Interventional Radiology department at the Interbalkan European Medical Center in Thessaloniki, Greece.

READ: Cosmos Holdings focuses on Europe as it expands its global wholesale pharmaceutical business

Cosmos CEO Grigorios Siokas is keen on Dedes’ elevation to the board, citing his healthcare expertise.

“Dr. Ioannis Dedes brings a wealth of experience to our group,” noted Siokas in a statement. “Dr. Dedes’s addition to our board will provide strategic and tactical support to our enterprise healthcare process, as well as our business development.”

Dedes’ appointment follows the recent addition of Anastasios Tzikas, the former CEO of Singular Northern Greece SA, one of Greece’s largest software vendors, to the Cosmos board.

Cosmos is an international pharmaceutical company with offices and distribution centers in Greece and the United Kingdom.

Cosmos shares slipped slightly to close at $6.99 on Tuesday.

Contact Ellen Kelleher at [email protected]

View full COSM profile View Profile

Cosmos Holdings Inc Timeline

Article
July 02 2018

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
scientist in lab
December 20 2018
Data from Midatech's MTD201 drug has validated the company's Q-Sphera sustained release technology, and other, bigger players are starting to sit up and take note
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use